The drug regulatory authorities of Japan and China are continuing to discuss issues related to participation in global clinical trials, information sharing and the influence of ethnic factors, as part of a broader collaboration between regulators in Northeast Asia1.
Japan's Pharmaceuticals and Medical Devices Agency co-hosted a symposium in Beijing with China's State Food and Drug Administration at the end of May, which focused on the exchange of information and the two countries' participation in international clinical development programmes...
Please login to read the full article.
